References
- Vale R, Reese T, Sheetz M. Identification of a novel force-generating protein, kinesin, involved in microtubule-based motility. Cell 1985;42:39–50.
- Schoumacher M, Goldman RD, Louvard D, et al. Skeleton key for metastasis. J Cancer Biol 2010;189:388–396.
- Persidis A. Cancer multidrug resistance. Nat Biotechnol 2000;18: IT18–IT20.
- Wolf S, Barton D, Kottschade L, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008;44:1507–1515.
- Visovsky C. Chemotherapy-induced peripheral neuropathy. Cancer Invest 2003;21:439–451.
- Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin. Neurol 2005;18:574–580.
- Holen KD, Belani CP, Wilding G, et al. A first human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemothe Pharmacol 2011;67:447–454.
- Bongero D, Paoluzzi L, Marchi E, et al. The novel kinesin spindle protein inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma. Leuk Lymphoma 2015; doi: 10.3109/10428194.2015.1020058
- Zain J, Bongero D, Goy A, et al. Translational development of the novel kinesin spindle protein (KSP/Eg5) inhibitor SB-743921 (SB-921) in lymphoma: from preclinical models to phase 1 studies. Poster presentation at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer, October 2008, Geneva, Switzerland.
- Doorduijn J, Buijt I, Holt B, et al. Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol 2005;75:116–123.
- Horner MJ, Ries LAG, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975–2006. Surveillance Epidemiology and End Results (SEER). Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2006/
- Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008;168:469–476.
- Cheson B, Leonard J. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008;359:613–626.
- Czuczman M, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711–4716.
- Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064–3071.
- Cheson B, Pfistner B, Juweid M, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
- Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
- Sutton D, Zhang SY, Diamond M, et al. Relationship between the antitumor activity of ispinesib, a novel KSP inhibitor, and neutropenia in a human xenograft model. Poster presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer, November 2005, Philadelphia, PA, USA.
- Kathman S, Williams D, Hodge J, et al. A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression. Cancer Chemother Pharmacol 2007;63:469–476.
- O’Connor OA, Gerecitano J, Van Deventer H, et al. A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed Q14D without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL). Poster presentation at 51st ASH Annual Meeting and Exposition, December 2009, New Orleans, LA, USA.